sponsored
PatientsVille.com Logo

PatientsVille

Hyperprolactinaemia Medical Research Studies

Up-to-date List of Hyperprolactinaemia Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Hyperprolactinaemia Medical Research Studies

Rank Status Study
1 Recruiting Peony-Glycyrrhiza Decoction (PGD) for Antipsychotic-induced Hyperprolactinemia in Patients With Schizophrenia
Conditions: Schizophrenia;   Schizophrenic Disorder;   Hyperprolactinemia;   Hyperprolactinaemia
Interventions: Drug: PGD granules;   Drug: Placebo
Outcome Measures: Changes from baseline Positive and Negative Syndrome Scale (PANSS) at 8 weeks and 16 weeks;   Changes from baseline Clinical Global Impression (CGI) score at 8 weeks and 16 weeks;   Changes from baseline Simpson-Angus Rating Scale (SAS) at 8 weeks and 16 weeks;   Changes from baseline Abnormal involuntary movement scale (AIMS) at 8 weeks and 16 weeks;   Change from baseline scores of Prolactin Related Adverse Event Questionnaire (PRAEQ) at 8 weeks and 16 weeks;   Change from baseline scores of Udvalg for Kliniske Undersøgelser Side Effect Rating Scale (UKU) at 8 weeks and 16 weeks
2 Unknown  Risperidone-Induced Hyperprolactinemia Treated With Bromocriptine
Conditions: Schizophrenia;   Hyperprolactinemia
Intervention: Drug: Bromocriptin
Outcome Measures: Prolactin;   LH;   FSH;   Testosterone;   Estradiol;   PANSS;   HAM-D;   Simpson Angus Scale (SAS)
3 Recruiting Substrate Metabolism and Insulin Sensitivity in Patients With Hyperprolactinemia Before and After Treatment
Conditions: Hyperprolactinemia;   Insulin Resistance
Intervention: Other: Cabergoline
Outcome Measures: Insulin sensitivity;   QoL, body composition, intrahepatic and intramyocellular fat, substrate metabolism, glucose tolerance
4 Recruiting Aripiprazole and Prolactin Study
Condition: Hyperprolactinemia
Intervention: Drug: Aripiprazole
Outcome Measures: Normalization or reduction in prolactin sufficient to restore gonadal function;   Normalization or improvement in bone mineral density
5 Recruiting Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia
Condition: Hyperprolactinemia
Interventions: Drug: Aripiprazole;   Drug: Placebo
Outcome Measures: To determine if adjunct aripiprazole will resolve or improve prolactin related hormonal side effects (amenorrhea, oligomenorrhea, galactorrhea).;   To test whether adjunctive aripiprazole will improve quality/perceived quality of life.;   To identify if adjunct aripiprazole will improve bone turnover as measured by assays of osteoblastic and osteoclastic activity.;   To examine side effects associated with adjunctive aripiprazole versus placebo and conduct a cost analysis of adjunctive aripiprazole use.;   To evaluate the mediator effects of estrogen, progesterone, prolactin effects on quality of life, bone turnover and sexual functioning.
6 Recruiting Adjunctive Aripiprazole in the Treatment of Risperidone-Induced Hyperprolactinemia
Condition: Schizophrenia
Intervention: Drug: Aripiprazole
Outcome Measures: Prolactin level;   PANSS (positive and negative syndrome scale) score
7 Unknown  Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia
Conditions: Hyperprolactinemia;   Weight Gain;   Dyslipidemia
Intervention: Drug: Abilify (aripiprazole)
Outcome Measure:
8 Recruiting Mathematical Model for the Human Menstrual Cycle, Endocrinological Diseases and Fertility Treatment-PAEON
Conditions: Polycystic Ovary Syndrome;   Endometriosis;   Hyperprolactinemia
Intervention: Other: Fertility treatment
Outcome Measures: Hormonal parameters;   Dynamics of fertility treatment
9 Recruiting A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders
Conditions: Sexual Dysfunction;   Hyperprolactinemia
Interventions: Drug: Aripiprazole;   Drug: risperidone or paliperidone
Outcome Measures: Change from baseline in severity of sexual/reproductive system dysfunction at 12 weeks;   Percentage of absence of sexual/reproductive system dysfunction on the UKU side effect rating scale or ASEX
10 Unknown  Efficacy of Rapid Escalation of Cabergoline in Comparison to Conventional Dosing in Prolactin Secreting Macroadenomas.
Condition: Macroprolactinoma
Interventions: Drug: Cabergoline;   Drug: cabergoline
Outcome Measures: Normoprolactinemia;   Duration for resolution of Hypogonadism
11 Recruiting Assessing Fertility Potential in Female Cancer Survivors
Condition: Effects of Chemotherapy
Intervention:
Outcome Measures: Reproductive hormones;   Antral Follicle Counts
12 Unknown  High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone
Conditions: Schizophrenia;   Schizoaffective Disorder
Interventions: Drug: long-acting injectable risperidone;   Drug: long acting injectable risperidone
Outcome Measures: The primary end point will be change in PANSS Positive Subscale Score in the high dose group using a mixed model ANOVA;   change in PANSS; time to discontinuation for lack of efficacy and tolerability; change in cognitive domain scores; comparative incidence and time course of EPS, hyperprolactinemia, plasma lipids, weight gain, and other side effects between treatments

These studies may lead to new treatments and are adding insight into Hyperprolactinaemia etiology and treatment.

A major focus of Hyperprolactinaemia research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Hyperprolactinaemia